( WALTHAM Mass.--(BUSINESS WIRE)--Jun 12...)July Issue of Journal of Antimicrobial Chemotherapy Highlights,Study of Factive Tablets for Five-Day Treatment of,Community-Acquired Pneumonia,Health

WALTHAM, Mass.--(BUSINESS WIRE)--Jun 12, 2007 - Results from the successful clinical trial of Oscient Pharmaceuticals' (Nasdaq: OSCI) FACTIVE(R) (gemifloxacin mesylate) tablets for the five-day treatment of community-acquired pneumonia of mild to moderate severity (CAP) have been published in the July issue of the peer-reviewed Journal of Antimicrobial Chemotherapy, currently available in advance on-line. The data from the Phase III clinical trial comparing a five-day and seven-day course of treatment with FACTIVE for CAP formed the basis of the approval last month from the U.S. Food and Drug Administration (FDA) of FACTIVE for the five-day treatment of CAP. FACTIVE 320 mg once-daily is the only fluoroquinolone antibiotic currently approved in the U.S. for the five-day treatment of both CAP and acute bacterial exacerbations of chronic bronchitis (AECB).

"The Phase III trial of FACTIVE demonstrated the efficacy of five-day FACTIVE to treat community-acquired pneumonia," stated Thomas File, M.D., Professor of Internal Medicine and Head of the Infectious Disease Section, Northeastern Ohio Universities College of Medicine and the lead author of the article. "The publication of these data are adding to the body of scientific evidence that demonstrates the importance of short courses of potent antibiotic therapy in treating community-acquired pneumonia, as recommended in the CAP treatment guidelines from the Infectious Diseases Society of America and the American Thoracic Society."

"Following approval last month, we have been discussing the shortened treatment duration for FACTIVE in CAP with physicians and are planning a larger-scale campaign for this fall, in advance of the respiratory tract infection season," stated Steven M. Rauscher, President and CEO of Oscient Pharmaceuticals. "Conducting a successful Phase III trial showing comparability between the five and seven-day treatment regimens for FACTIVE was
'"/>

Page: 1 2 3 4 5
Related medicine technology :

1. Vicals Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA Vaccine Performance; Yields Antibody Responses Comparable to Electroporation Without Tolerability Issues
2. FDA Issues Safety Alert on Avandia
3. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
4. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
5. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
6. New Study in Journal of Pediatrics Suggests Synagis (Palivizumab) May Reduce Subsequent Recurrent Wheezing in Preterm Infants
7. Genetics Journal Thimerosal/Autism Study the Best Science Drug Company Money Can Buy
8. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
9. Research on New Treatment for Neglected Disease Published in The New England Journal of Medicine
10. Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in Journal of American College of Cardiology
11. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics